The case of Myriad in the patentability of human genes has been a concern for many who believe in equal access, as it stops people from getting access to a more advanced step in testing for breast and ovarian cancer. It has been an issue brought up many times by many in the health industry. Originally, in 2010, the case for patenting these genes resulted in a ruling of these genes as "un-patentable."
In a more recent development, an appeal's court, the previous ruling was overturned, allowing the patents to stand. This is now being appealed to a higher federal district court.
The supreme court is putting pressure on the appeals court from the previous case to overturn their ruling, especially after they ruled a medical test unpatentable earlier this year.
Check out this article in the NY Times for more information: Here